- NSC781406
-
- $58.00
-
2026-07-27
- CAS:1676893-24-5
- Purity: 99.58%
- Supply Ability: 10g
|
| | NSC781406 Basic information |
| Product Name: | NSC781406 | | Synonyms: | NSC781406;NSC781406;NSC-781406;NSC 781406;NSC-781406;NSC 781406;Benzenesulfonamide, 2,4-difluoro-N-[2-methoxy-5-[4-[3-[4-(methylsulfonyl)-1-piperazinyl]-1-propyn-1-yl]-6-quinolinyl]-3-pyridinyl]-;NSC781406,Phosphoinositide 3-kinase,NSC 781406,NSC-781406,PI3K,Mammalian target of Rapamycin,Inhibitor,inhibit,mTOR;2,4-difluoro-N-[2-methoxy-5-[4-[3-[4-(methylsulfonyl)-1-piperazinyl]-1-propyn-1-yl]-6-quinolinyl]-3-pyridinyl]-benzenesulfonamide;NSC781406, 10 mM in DMSO | | CAS: | 1676893-24-5 | | MF: | C29H27F2N5O5S2 | | MW: | 627.68 | | EINECS: | | | Product Categories: | | | Mol File: | 1676893-24-5.mol |  |
| | NSC781406 Chemical Properties |
| Boiling point | 775.1±70.0 °C(Predicted) | | density | 1.52±0.1 g/cm3(Predicted) | | storage temp. | Store at -20°C | | solubility | DMF: 10mg/mL; DMSO: 20mg/mL; DMSO:PBS (pH 7.2) (1:4): 0.2mg/mL | | form | A solid | | pka | 6.23±0.40(Predicted) | | color | White to off-white |
| | NSC781406 Usage And Synthesis |
| Description | NSC 781406 is a dual inhibitor of PI3K and mammalian target of rapamycin (mTOR; IC50s = 2.0, 9.4, 2.7, 14, and 5.4 nM for PI3Kα, PI3Kβ, PI3Kγ, PI3Kδ, and mTOR, respectively). It inhibits cell growth in the NCI-60 panel of cancer cell lines (mean GI50 = 65 nM). NSC 781406 (30 mg/kg) reduces tumor volume in a BEL-7404 hepatic cancer mouse xenograft model. | | Uses | NSC781406 is a highly potent PI3K and mTOR inhibitor with an IC50 of 2 nM for PI3Kα. | | in vivo | In the xenograft models, treatment with 30 mg/kg of NSC781406 results in statistically significant antitumor activity, with a mean reduction in relative tumor volume ratio of 52%. Sorafenib displays an inhibition ratio of 44% at 50 mg/kg. NSC781406 is well tolerated at 30 mg/kg, with no observed mortality or significant reduction of body weight[1]. | | IC 50 | PI3Kα: 2 nM (IC50); PI3Kγ: 2.7 nM (IC50); PI3Kβ: 9.4 nM (IC50); PI3Kδ: 14 nM (IC50); mTOR: 5.4 nM (IC50) | | References | [1] Chen Y, et al. Discovery of benzenesulfonamide derivatives as potent PI3K/mTOR dual inhibitors with in vivo efficacies against hepatocellular carcinoma. Bioorg Med Chem. 2016 Mar 1;24(5):957-66. DOI:10.1016/j.bmc.2016.01.008 |
| | NSC781406 Preparation Products And Raw materials |
|